Switzerland's Galenica H1 sales rise on pharmacy services demand

Galenica AG

06/08/2026 05:49

Overview
Switzerland healthcare network's H1 sales grew 7.1% to CHF 2.14 bln
Adjusted EBIT for H1 rose 7.1% to CHF 117.7 mln

Outlook
Galenica confirms 2026 sales growth guidance of 5% to 7%
Company expects 2026 adjusted EBIT to increase by 6% to 8%
Galenica plans 2026 dividend at least at previous year's level

Result Drivers
PHARMACY SERVICES DEMAND - Co said rising demand for healthcare services and consultations in pharmacies supported sales growth
HOME CARE AND DIAGNOSTICS - Home care and diagnostics businesses established themselves as important growth drivers, per co
WHOLESALE MARKET SHARE - Co said Galexis gained market share in pharmacy wholesaling, helping drive segment growth

Company press release: ID:nEQbTNtJYa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
CHF 2.14 bln
 
H1 Adjusted EBIT
 
CHF 117.70 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 6 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for Galenica AG is CHF88.50, about 4.5% above its August 5 closing price of CHF84.65
The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 21 three months ago

Reuters Recommended Reads
Aug 5 - Switzerland's Sandoz H1 net sales rise on biosimilar growth
Aug 5 - McKesson raises annual profit forecast on strong growth in specialty drug business
Aug 5 - Pennant Group Q2 revenue beats estimates on home health and hospice growth

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)